More info…
Hungarian pharmaceutical company Gedeon Richter and its US partner Forest Laboratories announced on Monday that they are considering further Phase II dose-effect testing of their new investigational antipsychotic agent cariprazine based on the preliminary results of Phase II clinical trials of cariprazine for the treatment of bipolar depression.
Richter, Forest Laboratories consider further Phase II testing of cariprazine for depression
Subscribe
Subscribe to our e-mail newsletter to receive updates.
Leave a Reply
You must be logged in to post a comment.
No comments yet.